F Arias1, C Eito2, G Asín2, I Mora2, K Cambra3, F Mañeru4, B Ibáñez3, L Arbea5, A Viudez6, I Hernández6, J I Arrarás5, M Errasti5, M Barrado2, M Campo2, I Visus2, S Flamarique5, M A Ciga7. 1. Radiation Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, Pamplona, 31008, Spain. fariasde@cfnavarra.es. 2. Radiation Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, Pamplona, 31008, Spain. 3. Department of Statistics, Complejo Hospitalario de Navarra, Pamplona, Spain. 4. Department of Physics, Complejo Hospitalario de Navarra, Pamplona, Spain. 5. Radiation Oncology Department, Clinica Universitaria de Navarra, Pamplona, Spain. 6. Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain. 7. Department of Surgery, Complejo Hospitalario de Navarra, Pamplona, Spain.
Abstract
BACKGROUND: The objective of the study is to determine the correlations among the variables of dose and the sphincter function (SF) in patients with locally advanced rectal cancer treated with preoperative capecitabine/radiotherapy followed by low anterior resection (LAR) + TME. METHODS: We retrospectively reviewed 92 consecutive patients with LARC treated at our center with LAR from 2006 and more than 2 years free from disease. We re-contoured the anal sphincters (AS) of patients with the help of the radiologist. SF was assessed with the Wexner scale (0-20 points, being punctuation inversely proportional to annal sphincter functionality). All questionnaires were filled out between January 2010 and December 2012. Dosimetric parameters that have been studied include V 20, V 30, V 40, V 50, mean dose (D mean), minimum dose (D min), D 90 (dose received by 90% of the sphincter) and D 98. STATISTICAL ANALYSIS: The correlations among the variables of dose and SF were studied by the Spearman correlation coefficient. Differences in SF relating to maximum doses to the sphincter were assessed by the Mann-Whitney test. RESULTS: Mean Wexner score was 5.5 points higher in those patients with V 20 > 0 compared to those for which V 20 = 0 (p = 0.008). In a multivariate regression model, results suggest that the effect of V 20 on poor anal sphincter control is independent of the effect of distance, with an adjusted OR of 3.42. CONCLUSIONS: In order to improve the SF in rectal cancer treated with preoperative radiotherapy/capecitabine followed by conservative surgery, the maximum radiation dose to the AS should be limited, when possible, to <20 Gy.
BACKGROUND: The objective of the study is to determine the correlations among the variables of dose and the sphincter function (SF) in patients with locally advanced rectal cancer treated with preoperative capecitabine/radiotherapy followed by low anterior resection (LAR) + TME. METHODS: We retrospectively reviewed 92 consecutive patients with LARC treated at our center with LAR from 2006 and more than 2 years free from disease. We re-contoured the anal sphincters (AS) of patients with the help of the radiologist. SF was assessed with the Wexner scale (0-20 points, being punctuation inversely proportional to annal sphincter functionality). All questionnaires were filled out between January 2010 and December 2012. Dosimetric parameters that have been studied include V 20, V 30, V 40, V 50, mean dose (D mean), minimum dose (D min), D 90 (dose received by 90% of the sphincter) and D 98. STATISTICAL ANALYSIS: The correlations among the variables of dose and SF were studied by the Spearman correlation coefficient. Differences in SF relating to maximum doses to the sphincter were assessed by the Mann-Whitney test. RESULTS: Mean Wexner score was 5.5 points higher in those patients with V 20 > 0 compared to those for which V 20 = 0 (p = 0.008). In a multivariate regression model, results suggest that the effect of V 20 on poor anal sphincter control is independent of the effect of distance, with an adjusted OR of 3.42. CONCLUSIONS: In order to improve the SF in rectal cancer treated with preoperative radiotherapy/capecitabine followed by conservative surgery, the maximum radiation dose to the AS should be limited, when possible, to <20 Gy.
Authors: E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde Journal: N Engl J Med Date: 2001-08-30 Impact factor: 91.245
Authors: Corrie A M Marijnen; Cornelis J H van de Velde; Hein Putter; Mandy van den Brink; Cornelis P Maas; Hendrik Martijn; Harm J Rutten; Theo Wiggers; Elma Klein Kranenbarg; Jan-Willem H Leer; Anne M Stiggelbout Journal: J Clin Oncol Date: 2005-03-20 Impact factor: 44.544
Authors: Wouter Schaake; Arjen van der Schaaf; Lisanne V van Dijk; Alfons H H Bongaerts; Alfons C M van den Bergh; Johannes A Langendijk Journal: Radiother Oncol Date: 2016-05-03 Impact factor: 6.280
Authors: Richard J Stephens; Lindsay C Thompson; Phil Quirke; Robert Steele; Robert Grieve; Jean Couture; Gareth O Griffiths; David Sebag-Montefiore Journal: J Clin Oncol Date: 2010-06-28 Impact factor: 44.544
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Hendrik Dapper; Iván Rodríguez; Stefan Münch; Jan C Peeken; Kai Borm; Stephanie E Combs; Daniel Habermehl Journal: Radiat Oncol Date: 2018-12-03 Impact factor: 3.481
Authors: Antonia Regnier; Jana Ulbrich; Stefan Münch; Markus Oechsner; Dirk Wilhelm; Stephanie E Combs; Daniel Habermehl Journal: Front Oncol Date: 2017-09-20 Impact factor: 6.244
Authors: Ane L Appelt; Ellen M Kerkhof; Lars Nyvang; Ernst C Harderwijk; Natalie L Abbott; Mark Teo; Femke P Peters; Camilla J S Kronborg; Karen-Lise G Spindler; David Sebag-Montefiore; Corrie A M Marijnen Journal: Tech Innov Patient Support Radiat Oncol Date: 2019-10-15